Qurient Co., Ltd., a South Korea-based biotechnology company, has announced the publication of a peer-reviewed study in *Science Advances* highlighting the synergistic benefits of its selective CDK7 inhibitor, Q901, when combined with topoisomerase I inhibitor-based antibody-drug conjugates (TOP1i-ADCs). The findings are expected to contribute significantly to the company’s therapeutic strategies in cancer treatment.
Key Findings and Implications
The study, conducted in collaboration with scientists from Pohang University of Science and Technology, the U.S. National Cancer Institute, and the University of Maryland, demonstrates how Q901 enhances the antitumor effects of TOP1i-ADCs. Specifically, Q901 has been shown to inhibit MYC- and E2F-driven transcriptional pathways, consequently reducing the expression of critical homologous recombination repair (HRR) genes.
This action prolongs the presence of TOP1-DNA protein crosslinks (TOP1-DPCs), which increases the sensitivity of tumor cells to both standalone TOP1 inhibitors and TOP1i-ADCs. Kiyean Nam, Ph.D., CEO of Qurient and one of the study’s co-authors, commented on the potential for improving progression-free survival rates through this approach.
Among the key findings outlined in the publication are:
- Highly Selective Inhibition: Q901 demonstrated notable selectivity for CDK7, forming a covalent bond with the protein.
- Disruption of Oncogenic Pathways: The compound effectively suppressed transcriptional programs governed by MYC and E2F, which are crucial for DNA damage repair.
- Increased TOP1-DPC Longevity: Inhibition of CDK7 was found to reduce the clearance of TOP1-DPCs, amplifying DNA damage within tumor cells.
- Improved Outcomes with Various TOP1i-ADCs: Preclinical models indicated a significant increase in antitumor activity when Q901 was administered alongside leading ADCs.
The insights gleaned from this research provide a foundational element for Qurient’s strategy to enhance existing ADC therapies through combination treatments and develop advanced dual-payload ADCs that incorporate both CDK7 and TOP1 inhibitors into single therapeutic regimens.
Qurient, a clinical-stage biotechnology firm, continues to expand its pipeline focused on innovative cancer therapeutics. The study signifies progress in their development of Q901 and the planned dual-payload ADCs that aim to address a spectrum of cancer types.
Why It Matters
This research not only underscores the potential for novel therapeutic strategies in cancer treatment but also highlights the importance of combination therapies in enhancing the efficacy of existing modalities. As the landscape of cancer treatment evolves, findings such as these play a critical role in informing clinical practices and guiding future innovations.
